Compare ONDS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONDS | NUVB |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | N/A | N/A |
| Metric | ONDS | NUVB |
|---|---|---|
| Price | $8.54 | $9.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $10.00 | ★ $10.63 |
| AVG Volume (30 Days) | ★ 76.5M | 6.0M |
| Earning Date | 11-13-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $24,748,922.00 | ★ $26,748,000.00 |
| Revenue This Year | $417.68 | $609.55 |
| Revenue Next Year | $244.11 | $197.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 208.40 | ★ 1137.19 |
| 52 Week Low | $0.57 | $1.54 |
| 52 Week High | $11.70 | $9.75 |
| Indicator | ONDS | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 69.97 |
| Support Level | $8.67 | $9.06 |
| Resistance Level | $9.84 | $9.75 |
| Average True Range (ATR) | 0.91 | 0.48 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 47.48 | 82.31 |
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.